| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
CKK-E12 targets the delivery of RNA-based therapeutics to liver parenchymal cells. It is an ionizable lipid used in LNPs for RNA delivery. The lipid is highly selective for liver parenchymal cells in vivo. It is used for efficient delivery of siRNA and mRNA.
|
|---|---|
| ln Vitro |
In vitro, CKK-E12 is used as an ionizable lipid in LNPs for RNA delivery. It is used in combination with other lipids to form LNPs. The LNPs are used for efficient delivery of siRNA and mRNA.
|
| ln Vivo |
In vivo, CKK-E12 is highly selective toward liver parenchymal cells. It is used for efficient delivery of siRNA and mRNA to the liver. LNPs containing CKK-E12 are used for RNA-based research and therapeutics.
|
| Enzyme Assay |
There are no in vitro enzyme/receptor binding assays for CKK-E12 as it is a lipid for RNA delivery, not an enzyme inhibitor. Its function is assessed by its ability to deliver RNA into cells.
|
| Cell Assay |
In vitro cell-based assays for CKK-E12 involve formulating the lipid into LNPs with RNA and treating cells with the LNPs. RNA delivery efficiency is assessed by measuring gene knockdown (for siRNA) or protein expression (for mRNA). Cell viability and toxicity are also evaluated.
|
| Animal Protocol |
In vivo animal studies for CKK-E12 involve administering CKK-E12 LNPs containing RNA to mice via intravenous injection. RNA delivery to the liver is assessed by measuring target gene knockdown or protein expression in liver tissue. The lipid's selectivity for liver parenchymal cells is evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of CKK-E12 are not extensively detailed in the available literature. For storage, it should be kept at -20°C.
|
| Toxicity/Toxicokinetics |
No specific toxicity data for CKK-E12 are available in the provided literature. The compound is for research use only. Standard laboratory safety precautions should be followed when handling.
|
| References |
|
| Additional Infomation |
CKK-E12 is an ionizable lipid for RNA delivery. It is highly selective for liver parenchymal cells. It is used for efficient delivery of siRNA and mRNA. Its CAS number is 1432494-65-9.
|
| Molecular Formula |
C60H120N4O6
|
|---|---|
| Molecular Weight |
993.62
|
| Exact Mass |
992.92
|
| Elemental Analysis |
C, 72.53; H, 12.17; N, 5.64; O, 9.66
|
| CAS # |
1432494-65-9
|
| Related CAS # |
1432494-65-9;
|
| PubChem CID |
71555845
|
| Appearance |
Pale yellow viscous liquid
|
| LogP |
18.7
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
54
|
| Heavy Atom Count |
70
|
| Complexity |
1010
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCC(CN(CCCCC1C(=O)NC(C(=O)N1)CCCCN(CC(CCCCCCCCCC)O)CC(CCCCCCCCCC)O)CC(CCCCCCCCCC)O)O
|
| InChi Key |
ZISVTYVLWSZJAL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C60H120N4O6/c1-5-9-13-17-21-25-29-33-41-53(65)49-63(50-54(66)42-34-30-26-22-18-14-10-6-2)47-39-37-45-57-59(69)62-58(60(70)61-57)46-38-40-48-64(51-55(67)43-35-31-27-23-19-15-11-7-3)52-56(68)44-36-32-28-24-20-16-12-8-4/h53-58,65-68H,5-52H2,1-4H3,(H,61,70)(H,62,69)
|
| Chemical Name |
3,6-bis[4-[bis(2-hydroxydodecyl)amino]butyl]piperazine-2,5-dione
|
| Synonyms |
CKK-E12; CKKE12; CKK E12; O-8744; O8744; O 8744;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~50.32 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0064 mL | 5.0321 mL | 10.0642 mL | |
| 5 mM | 0.2013 mL | 1.0064 mL | 2.0128 mL | |
| 10 mM | 0.1006 mL | 0.5032 mL | 1.0064 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
